Alpharma Ups Ante With Phase III Embeda Proof
This article was originally published in The Pink Sheet Daily
Executive Summary
Pain drug’s data could help lure more than King to the table.
You may also be interested in...
FDA Cmte. Will Discuss Standards For Abuse-Deterrant Pain Drugs, With Focus On Embeda
Approvability of Alpharma’s abuse-resistant morphine Embeda will facilitate a broader discussion of approval standards by advisory committees Nov. 14.
FDA Cmte. Will Discuss Standards For Abuse-Deterrant Pain Drugs, With Focus On Embeda
Approvability of Alpharma’s abuse-resistant morphine Embeda will facilitate a broader discussion of approval standards by advisory committees Nov. 14.
King Appeals Directly To Alpharma Investors To Clear Buyout
New offer gives Alpharma a “go-shop” option to find a better price elsewhere.